TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

TTENK/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice.TENK is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities TENK rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. TENK/calls is an independent service and is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

TTENK/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›MOH

MOH

MOLINA HEALTHCARE, INC.

Next earnings Jul 21, 2026 (after close) · consensus $1.45 EPS, $10.9B rev

Last earnings +1.3% on 2026-04-22

Hold
$229.87
▲ +0.14%
$229.87▼ -22.62%
over 1Y
L $122.65H $306.29
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.1%
1W+6.4%
1M+27.8%
3M+64.9%
YTD+28.8%
1Y-22.6%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
C+
Valuation
Overvalued
Filings
Flagged
Hold
Conviction
Horizon
Medium (3–12mo)
12-mo target
$•••
Street · 24 analysts
Hold

Medicaid premiums aren't keeping up with medical costs — earnings fell 60% — and at 22x there's no margin-of-safety on a recovery.

Revenue (FY2025) $45.4B · FY2025

The read

Middling fundamentals and a rich price (~72% above fair value) leave little margin of safety — a wait-and-see.

Molina Healthcare is a government-sponsored managed-care insurer (Medicaid, Medicare, Marketplace) whose FY2025 captures the sector-wide margin squeeze. Membership and premiums kept growing — revenue rose 11.7% to $45.4B — but profitability collapsed: net income fell 60.0% to $472M, operating income dropped 54.2% to $781M, and diluted EPS fell 56.3% to $8.92. The cause is exactly what the 10-K warns about: 'medical expenses have risen higher than anticipated, and our capitation rates have not kept pace,' compressing medical margins. Operating margin is now razor-thin at 1.7% and net margin just 1.0%, the inherent reality of a high-volume, fixed-premium model.

The balance sheet absorbed the hit. Equity fell 9.5% to $4.07B while long-term debt rose 28.8% to $3.77B (2.83x liabilities/equity), and operating cash flow swung to -$535M (a 183.1% deterioration), though insurer operating cash flow is heavily timing-driven by premium/claims cycles. Management leaned into buybacks anyway — $1.00B repurchased, cutting shares 7.2% — a vote of confidence that the rate/cost gap is cyclical rather than permanent.

AI-generated analysis, produced by our proprietary engine from SEC filing data.

Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jun 21, 2026, 4:50 PM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.

Financials · annual, by fiscal year

Line itemFY21FY22FY23FY24FY25
Revenue$27.8B$32.0B$34.1B$40.6B$45.4B
Gross profit—————
Operating income$1.02B$1.17B$1.57B$1.71B$781M
Net income$659M$792M$1.09B$1.18B$472M
Diluted EPS$11.25$13.55$18.77$20.42$8.92
Net margin2.4%2.5%3.2%2.9%1.0%

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$11.5B
EV / EBITDA11.8
EV / Sales0.3
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield3.9%
FCF yield-5.3%

Quality & risk

ROIC (est.)7.9%
Free cash flow-$636M
Total debt$3.77B
Net cash$482M
Altman Z-Score4.42 safe
Piotroski F-Score4/9

Capital returns

Buyback yield8.3%
Dividend yield (est.)—
Shareholder yield8.3%
Shares Δ YoY-7.2%

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — material impairment (2026-02-06). Worth a closer look.
  1. 8-K Reg FD disclosure2026-06-10
  2. 8-K Officer / director change2026-05-11
  3. 8-K Reg FD disclosure2026-05-08
  4. 10-Q Quarterly report2026-04-23
  5. 8-K Earnings results2026-04-22
  6. DEF 14A Proxy statement2026-03-23
  7. 8-K Reg FD disclosure2026-02-26
  8. 10-K Annual report2026-02-10
  9. 8-K Material impairment2026-02-06

Recent filings

all on EDGAR ↗
4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-07-012026-07-02open ↗4Period ending 2026-06-302026-07-02open ↗4Period ending 2026-06-302026-07-02open ↗4Period ending 2026-06-302026-07-02open ↗

Quality score

C+
ValueGrowthProfitHealthMom.
ValueB+
GrowthD
ProfitabilityC-
Financial healthB-
MomentumA
  • ✓Revenue growing year-over-year
  • ✓Profitable (positive net income)
  • ✗Net margin above 10%
  • ✗Return on equity above 15%
  • ✗Liabilities below 2× equity
  • ✗P/E below 25

Fair value est.

$64.83

Overvalued -72% vs price

cheapfair valueexpensive

Modified Graham: EPS $8.92 × (8.5 + 1.5 × 0.0% growth) × 0.85 quality = 7.3× multiple. An estimate, not a price target.

122.6552-week237.22
Revenue
$45.4B
+11.7% YoY
Net margin
1.0%
ROE
11.6%
P/E
25.8

SEC fundamentals · FY 2025

'21'22'23'24'25

■ revenue · ■ net income, by fiscal year

Revenue$45.4B+11.7%
Net income$472M-60.0%
Gross profit$2.48B+7.6%
Operating income$781M-54.2%
Diluted EPS$8.92-56.3%
Cash & equivalents$4.25B-8.9%
Total assets$15.6B-0.4%
Total liabilities$11.5B+3.2%
Stockholders' equity$4.07B-9.5%
Gross: 5.5%Op.: 1.7%L/E: 2.83x

Frequently asked

Is MOLINA HEALTHCARE, INC. (MOH) a buy?
MOH currently carries a Hold rating with 3/5 conviction, derived from its latest SEC filings. Medicaid premiums aren't keeping up with medical costs — earnings fell 60% — and at 22x there's no margin-of-safety on a recovery.
What is MOH's fair value?
A Modified-Graham model based on MOH's SEC fundamentals estimates a fair value of about $64.83. It is an estimate from reported earnings, not a price target.
Is MOH overvalued or undervalued?
Against a Modified-Graham fair-value estimate, MOH currently appears overvalued relative to its SEC-grounded earnings power.
What is MOLINA HEALTHCARE, INC.'s quality score?
MOH scores 63.531292546270635/100 (grade C+) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0001179929, latest 10-Q filed 2026-04-23) · EODHD · Proprietary analysis · as of 6/21/2026, 8:50:01 PM.

Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Insider activity

Form 4 · SEC
2026-07-01
ZORETIC RICHARD C
Director
Award237.00 @ $232.55$55.1K
2026-07-01
WOLF DALE B
Director
Award237.00 @ $232.55$55.1K
2026-07-01
Schapiro Richard M
Director
Award237.00 @ $232.55$55.1K
2026-07-01
ROMNEY RONNA
Director
Award237.00 @ $232.55$55.1K
2026-07-01
ORLANDO STEVEN J
Director
Award237.00 @ $232.55$55.1K
2026-07-01
Lockhart Stephen H
Director
Award237.00 @ $232.55$55.1K
2026-07-01
GROHOWSKI LEO P
Director
Award237.00 @ $232.55$55.1K
2026-07-01
SOISTMAN FRANCIS S JR
Director
Award237.00 @ $232.55$55.1K

Earnings history

beat/miss · move
2026-04-22Beat +21.0% est▲ +1.32%8-K ↗
2026-02-05Miss -916.0% est▼ -0.67%8-K ↗
2025-10-22Miss -53.3% est▼ -0.85%8-K ↗
2025-07-23Miss -6.3% est▲ +5.32%8-K ↗
2025-07-07Miss -6.3% est▼ -2.91%8-K ↗
2025-04-23—▲ +3.38%8-K ↗

Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.

Congressional trades

all activity →

Disclosed under the STOCK Act

2025-12-15Gilbert CisnerosSell$1.00K–$15.0KPTR ↗
2025-10-07Byron DonaldsSell$1.00K–$15.0KPTR ↗
2025-09-12Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-06-09Rob BresnahanBuy$1.00K–$15.0KPTR ↗
2025-06-06Gilbert CisnerosSell$1.00K–$15.0KPTR ↗
2025-05-06Gilbert CisnerosBuy$1.00K–$15.0KPTR ↗
2025-02-13Rob BresnahanSell$1.00K–$15.0KPTR ↗
2023-08-13Daniel GoldmanSell$15.0K–$50.0KPTR ↗
2023-07-12Earl BlumenauerBuy$15.0K–$50.0KPTR ↗
2023-05-19Daniel GoldmanBuy$15.0K–$50.0KPTR ↗

Self-reported periodic transaction reports (STOCK Act). Amounts are disclosed ranges; a trade may be a spouse's. Disclosures lag the trade by up to ~45 days. Source: House Clerk + Senate eFD.

Recent news

market news →
Q1 Rundown: Molina Healthcare (NYSE:MOH) Vs Other Health Insurance Providers StocksBullish
finance.yahoo.com· 2026-07-03
Q1 Earnings Highs And Lows: UnitedHealth (NYSE:UNH) Vs The Rest Of The Health Insurance Providers StocksBullish
finance.yahoo.com· 2026-07-02
Spotting Winners: Clover Health (NASDAQ:CLOV) And Health Insurance Providers Stocks In Q1Bullish
finance.yahoo.com· 2026-07-02
Vanguard Small-Cap Value ETF Tops State Street on Cost and YieldBullish
nasdaq.com· 2026-07-02
Vanguard Small-Cap Value ETF Tops State Street on Cost and YieldBullish
finance.yahoo.com· 2026-07-02
Is Molina Healthcare (MOH) Stock Undervalued Right Now?Bullish
finance.yahoo.com· 2026-07-01

Vs tracked universe

compare →

1194 tracked peers · median

TENK Score64 vs 67
Revenue growth11.7% vs 7.5%
Net margin1.0% vs 10.0%
Return on equity11.6% vs 12.0%
P/E25.8 vs 26.2

News sentiment

EODHD · 33d
Bullish
+0.17
vs typical · 54 articles
↑ improving

Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.